



Early View

Research letter

Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥ 500 cells· μL^{-1}

Klaus F. Rabe, Ian D. Pavord, Mario Castro, Michael E. Wechsler, Nadia Daizadeh, Upender Kapoor, Benjamin Ortiz, Amr Radwan, Robert R. Johnson, Paul J. Rowe, Yamo Deniz, Juby A. Jacob-Nara

Please cite this article as: Rabe KF, Pavord ID, Castro M, *et al.* Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥ 500 cells· μL^{-1} . *Eur Respir J* 2022; in press (<https://doi.org/10.1183/13993003.02577-2021>).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org

Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥ 500 cells/ μ L

Klaus F. Rabe^{1,2}, Ian D. Pavord³, Mario Castro⁴, Michael E. Wechsler⁵, Nadia Daizadeh⁶, Upender Kapoor⁷, Benjamin Ortiz⁸, Amr Radwan⁸, Robert R. Johnson⁷, Paul J. Rowe⁷, Yamo Deniz⁸ and Juby A. Jacob-Nara⁷

¹LungenClinic Grosshansdorf (member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Grosshansdorf, Germany. ²Christian-Albrechts University (member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Kiel, Germany. ³NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. ⁴Division of Pulmonary, Critical Care, and Sleep Medicine, University of Kansas School of Medicine, Kansas City, KS, USA. ⁵Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA. ⁶Sanofi, Cambridge, MA, USA. ⁷Sanofi, Bridgewater, NJ, USA. ⁸Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.

Correspondence: Klaus F. Rabe, LungenClinic Grosshansdorf GmbH, Wöhrendamm 80, 22927 Grosshansdorf, Germany. E-mail: k.f.rabe@lungenclinic.de. Phone: 04102 / 601-2001

Acknowledgements:

The authors thank Arman Altincatal for statistical support. Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT02414854. Medical writing/editorial assistance was provided by Erin McClure Carroll, PhD, of Excerpta Medica, and was funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc., according to the [Good Publication Practice guideline](#).

Support statement:

Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.

Conflict of interest:

K.F. Rabe is a consultant for and received speaker fees from AstraZeneca, Boehringer Ingelheim, Novartis, Sanofi and Teva. I.D. Pavord received speaker fees from Aerocrine AB, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Teva; received payments for organizing education events from AstraZeneca and Teva; received consulting fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Dey Pharma, Genentech, GlaxoSmithKline, Knopp Biosciences, Merck, MSD, Napp Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, Inc.,

RespiVert, Sanofi, Schering-Plough and Teva; has received international scientific meeting sponsorship from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Napp Pharmaceuticals and Teva; received research grant from Chiesi; and is consultant for Regeneron Pharmaceuticals, Inc. and Sanofi. M. Castro received research support from American Lung Association, AstraZeneca, GlaxoSmithKline, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis and Shionogi; is a consultant for Genentech, Novartis, sanofi-aventis and Teva; received speaker fees from AstraZeneca, Genentech, GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., Sanofi and Teva; received royalties from Elsevier. M.E. Wechsler reports personal fees from AstraZeneca, Boehringer Ingelheim, Equillium, Gala Therapeutics, Genentech, Genzyme, Mylan, Novartis, Pulmatrix, ResTORbio, Regeneron Pharmaceuticals, Inc., Sentien Biotechnologies and Teva; and grants and personal fees from GlaxoSmithKline and Sanofi. N. Daizadeh, U. Kapoor, R.R. Johnson, P.J. Rowe and J.A. Jacob-Nara are employees and may hold stock and/or stock options in Sanofi. B. Ortiz, A. Radwan and Y. Deniz are employees and shareholders of Regeneron Pharmaceuticals, Inc.

Take-home message:

Dupilumab is well tolerated and improves clinical outcomes in patients with asthma and high eosinophils (≥ 500 cells/ μ L). Improvements in clinical outcomes correlate with eosinophil counts, demonstrating dupilumab efficacy in patients with high eosinophils.

To the Editor:

Uncontrolled, moderate-to-severe asthma in patients with high baseline blood eosinophils (≥ 500 cells/ μL) can be difficult to treat [1]. Global Initiative for Asthma guidelines recommend biologics as add-on therapy for patients with severe type 2 inflammatory asthma that remains uncontrolled despite treatment with high-dose inhaled corticosteroids [2]. Surrogate markers of type 2 inflammation such as elevated levels of blood or sputum eosinophils and fractional exhaled nitric oxide (FeNO) can be used to identify patients with a type 2 signature who might be eligible for such treatment [1–3]. Several biologics are now available that target different molecules in type 2 inflammatory pathways, notably IgE and type 2 cytokines [1–3]. One of these, dupilumab, is a fully human VelocImmune[®]-derived [4, 5] monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, cytokines that are key and central drivers of type 2 inflammation in multiple diseases, thus inhibiting their signalling [6, 7].

In the phase 3 LIBERTY ASTHMA QUEST study (NCT02414854), add-on dupilumab 200 mg and 300 mg every 2 weeks (q2w) *versus* matched placebo significantly reduced severe asthma exacerbations and improved pre-bronchodilator forced expiratory volume in 1 second (FEV₁) in the overall population of patients with uncontrolled, moderate-to-severe asthma [8]. In this, and other studies, the magnitude of these benefits was greater in subgroups of patients with a type 2 signature (eosinophils ≥ 150 or ≥ 300 cells/ μL , and/or FeNO ≥ 25 ppb [parts per billion] or ≥ 50 ppb) [8–12]. Asthma control, assessed using the patient-reported 5-item Asthma Control Questionnaire (ACQ-5), was also significantly improved with dupilumab *versus* placebo in patients with elevated baseline eosinophil counts [10]. Moreover, dupilumab is effective in lowering biomarkers of type 2 inflammation in both the airway (FeNO) and blood compartments (serum thymus and activation-regulated chemokine and serum IgE) [8, 10, 11]. However, the efficacy and safety of dupilumab in patients with high eosinophil levels (≥ 500 cells/ μL) is not well understood.

In this *post hoc* analysis, we assessed the efficacy of dupilumab in patients enrolled in QUEST who had baseline blood eosinophils ≥ 500 cells/ μL . QUEST was a phase 3, randomised, controlled trial that evaluated the efficacy and safety of dupilumab in patients aged ≥ 12 years with uncontrolled, moderate-to-severe asthma [8]. QUEST was open to patients irrespective of minimum baseline blood eosinophil count or any other biomarker requirement. Patients were randomised 2:2:1:1 to receive 52 weeks of add-on therapy with subcutaneous dupilumab at a dose of 200 mg or 300 mg q2w or a matched-volume placebo (1.14 mL or 2.00 mL, respectively) for each active dose. The study was conducted in

accordance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guideline and was approved by local institutional review boards or ethics committees. All patients provided written informed consent before participating in the trial.

The efficacy endpoints in this analysis were the annualised severe exacerbation rate over the treatment period, mean change from baseline in pre-bronchodilator FEV₁ over time, and change from baseline at week 52 in ACQ-5 score in the subgroup of patients with baseline blood eosinophils ≥ 500 cells/ μ L. Annualised severe exacerbation rates were determined using a negative binomial model. Least squares (LS) mean change from baseline in pre-bronchodilator FEV₁ and ACQ-5 values were derived from a linear mixed-effect model with repeated measures. Spline regression analyses were performed on the overall intention-to-treat (ITT) population of QUEST to assess the effects of treatment by baseline eosinophil count on annualised severe exacerbation rates and change from baseline in pre-bronchodilator FEV₁ at weeks 12 and 52.

The ITT population of QUEST comprised 1902 patients. Of these, 436 (23%) had baseline eosinophil counts ≥ 500 cells/ μ L (145 randomised to dupilumab 200 mg q2w, 76 to placebo matched to dupilumab 200 mg, 141 to dupilumab 300 mg q2w and 74 to placebo matched to dupilumab 300 mg). Baseline demographics and clinical characteristics were comparable across the four treatment groups. The mean age of the patients ranged from 46.0 to 49.0 years across treatment groups, and 48.7%–63.1% were female. The mean number of severe exacerbations experienced in the previous year ranged from 2.3 to 2.6, baseline pre-bronchodilator FEV₁ from 1.70 to 1.72 L and ACQ-5 scores from 2.7 to 2.8 across treatment groups. Baseline median levels (interquartile range) of blood eosinophils and baseline FeNO across treatment groups ranged from 690.0 (600.0–950.0) to 795.0 (630.0–1030.0) cells/ μ L and from 35.0 (22.0–61.5) to 42.5 (29.0–72.5) ppb, respectively, indicative of, and confirming, the type 2 signature of the patients.

In patients with blood eosinophils ≥ 500 cells/ μ L at baseline, dupilumab 200 mg and 300 mg q2w *versus* placebo significantly reduced severe exacerbations by 74% and 71%, respectively (both $p < 0.0001$ vs matched placebo) (figure 1a), and improved pre-bronchodilator FEV₁ at week 52 by 0.37 L (95% confidence interval [CI] 0.26–0.49) and 0.30 L (95% CI 0.18–0.42), respectively; both $p < 0.0001$. As described in other dupilumab studies [8–12], improvements in FEV₁ were rapid, with significant differences *versus* placebo achieved as early as at the first evaluation at week 2 and were then sustained throughout the 52-week treatment period for both doses (both $p < 0.0001$ vs matched placebo at all timepoints) (figure 1b). Spline regression analyses revealed that, for both dupilumab doses, the

estimated rate of severe exacerbations decreased and improvements in pre-bronchodilator FEV₁ at weeks 12 and 52 increased with increasing levels of baseline blood eosinophils (figure 1c and 1d). Asthma control, as assessed using the ACQ-5, was also significantly improved at week 52 *versus* placebo (LS mean change [95% CI] from baseline: -0.59 [-0.88 to -0.30] and -0.62 [-0.92 to -0.33], respectively; p<0.0001 vs matched placebo), achieving the minimal clinically important difference of 0.5 [13] for both doses.

The incidence of adverse events was similar across dupilumab- and placebo-treated patients with uncontrolled moderate-to-severe asthma with blood eosinophils ≥500 cells/μL at baseline. The most common treatment-emergent adverse events reported overall in these patients were viral upper respiratory tract infection (20.2%), injection-site reactions (20.0%), upper respiratory tract infection (12.8%) and bronchitis (12.2%). In patients with blood eosinophils ≥500 cells/μL, on-treatment eosinophilia (defined as >3000 cells/μL) was reported by 10.3% and 9.2% of patients receiving 200 and 300 mg dupilumab, respectively, and by <3% of patients in the matching placebo groups. Elevated eosinophils and clinical symptoms were not correlated; 1 of 28 dupilumab-treated patients with eosinophilia developed eosinophilic granulomatosis with polyangiitis.

Patients with asthma with high blood eosinophil counts experience more severe exacerbations and have poorer asthma control; moreover, this relationship is continuous and linear with asthma outcomes worsening progressively with increasing baseline eosinophil count [14]. Findings from spline regression analyses concur with the literature, showing that dupilumab benefits increase with increasing baseline eosinophil concentration. Alongside previous data showing that the magnitudes of improvements in exacerbation rates, lung function and asthma control with dupilumab treatment *versus* placebo are greater in patients with a type 2 signature [8–12], the data presented here suggest that dupilumab may provide the greatest benefit to patients with a high type 2 signature, though results should be interpreted with caution as this was a post hoc analysis. Despite this limitation, the data also suggest that baseline eosinophil count has clinical utility in guiding treatment by identifying the patients who could benefit most from dupilumab treatment.

References

- 1 Kostikas K, Brindicci C, Patalano F. Blood eosinophils as biomarkers to drive treatment choices in asthma and COPD. *Curr Drug Targets* 2018; 19: 1882–1896.
- 2 Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2021. <https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf>. Date last updated: 2021. Date last accessed: 7 September 2021.
- 3 Schleich F, Demarche S, Louis R. Biomarkers in the management of difficult asthma. *Curr Top Med Chem* 2016; 16: 1561–1573.
- 4 Macdonald LE, Karow M, Stevens S, *et al*. Precise and in situ genetic humanization of 6 mb of mouse immunoglobulin genes. *Proc Natl Acad Sci U S A* 2014; 111: 5147–5152.
- 5 Murphy AJ, Macdonald LE, Stevens S, *et al*. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. *Proc Natl Acad Sci U S A* 2014; 111: 5153–5158.
- 6 Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. *Expert Rev Clin Immunol* 2017; 13: 425–437.
- 7 Le Floc'h A, Allinne J, Nagashima K, *et al*. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R α antibody, is required to broadly inhibit type 2 inflammation. *Allergy* 2020; 75: 1188–1204.
- 8 Castro M, Corren J, Pavord ID, *et al*. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. *N Engl J Med* 2018; 378: 2486–2496.
- 9 Rabe KF, Nair P, Brusselle G, *et al*. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. *N Engl J Med* 2018; 378: 2475–2485.
- 10 Wenzel S, Castro M, Corren J, *et al*. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β 2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet* 2016; 388: 31–44.
- 11 Corren J, Castro M, O'Riordan T, *et al*. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. *J Allergy Clin Immunol Pract* 2020; 8: 516–526.
- 12 Castro M, Rabe KF, Corren J, *et al*. Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. *ERJ Open Res* 2020; 6: 00204–2019.
- 13 Juniper EF, Svensson K, Mork AC, *et al*. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. *Respir Med* 2005; 99: 553–558.
- 14 Price DB, Rigazio A, Campbell JD, *et al*. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. *Lancet Respir Med* 2015; 3: 849–858.

Figure Legend

FIGURE 1 (a) Annualised severe exacerbation rates over the treatment period and (b) LS mean change from baseline in pre-bronchodilator FEV₁ over time in patients with blood eosinophils ≥ 500 cells/ μ L at baseline. (c) Annualised severe exacerbation rates and (d) LS mean change from baseline in pre-bronchodilator FEV₁ in the overall ITT population by baseline eosinophil count.

BD: bronchodilator; CI: confidence interval; FEV₁: forced expiratory volume in 1 second; ITT: intention-to-treat; LS: least squares; q2w: every 2 weeks; SE: standard error. ***p<0.001.

■ Matching placebo to dupilumab 200 mg q2w ■ Dupilumab 200 mg q2w
■ Matching placebo to dupilumab 300 mg q2w ■ Dupilumab 300 mg q2w

